21 results about "Streptococcus pneumoniae bacteria" patented technology

The invention belongs to the technical field of molecular biology, and particularly relates to a construction method and application of a streptococcus pneumoniae pneumonia animal model. The invention provides a construction method of a streptococcus pneumoniae infected rat pneumonia and kidney injury model. The method comprises the following steps: S1, applying a streptococcus pneumoniae liquid into the respiratory tract of a rat by adopting an atomization bacterium feeding mode; and S2, verifying whether the rat treated in the step S1 is infected with pneumonia or not and whether kidney injury exists or not. According to the method, whether pneumonia is infected or not is judged by detecting inflammatory factors in alveolar lavage and lung HE staining, and whether kidney injury exists or not is judged by detecting the urine protein / creatinine ratio in a rat urine sample and detecting kidney HE staining. The construction method provided by the invention is convenient to operate, accurate in model construction and high in survival rate.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. The immunogenic compositions of the invention typically comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. The present invention also relates to the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection using said novel immunogenic compositions.

This invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular glycoantigens (glycoconjugates) and their uses. The immunogenic compositions of this invention will generally comprise at least one glycoconjugate derived from a Streptococcus pneumoniae serotype not found in Prevnar, Synflorix, and / or Prevnar 13. This invention also relates to the use of said novel immunogenic compositions for the vaccination of human subjects, particularly infants and the elderly, against pneumococcal infection.

The invention is related to 26-valent immunogenic compositions comprising 26 different S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. The 26-valent immunogenic compositions are useful for providing protection against S. pneumoniae infection and / or pneumococcal diseases caused by S. pneumoniae including pneumococcal pneumoniae, invasive pneumococcal disease and acute otitis media.

The present invention provides an immunogenic composition comprising a Streptococcus pneumoniae polysaccharide-protein conjugate, comprising a capsular polysaccharide derived from one or more selected from the group consisting of serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F, derived from Streptococcus pneumoniae; and one or 2 or more of carrier proteins conjugated to the respective capsular polysaccharide, and method of preparation thereof. Through one example of the present invention, an immunogenic composition for preventing or treating pneumococcal infection can be provided.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The invention discloses a primer probe composition and a method for simultaneously detecting five pneumonia pathogens on site, and relates to the technical field of biological detection. The invention provides a primer probe combination for on-site detection of pneumonia pathogens. The primer probe combination comprises a primer pair and a probe for detecting streptococcus pneumoniae, the primer pair and the probe are used for detecting klebsiella pneumoniae; the primer pair and the probe are used for detecting legionella pneumophila; the primer pair and the probe are used for detecting chlamydia pneumoniae; the invention discloses a primer pair and a probe for detecting mycoplasma pneumoniae. The method for detecting the pneumonia pathogens by adopting the primer probe combination and the kit disclosed by the invention integrates sample pretreatment, nucleic acid extraction, purification, amplification and detection, has better sensitivity and accuracy, is simple, convenient, rapid and time-saving to operate, and plays an important role in on-site rapid detection of the pneumonia pathogens.

The invention is related to 26-valent immunogenic compositions comprising 26 different S. pneumoniae polysaccharide carrier protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. The 26-valent immunogenic compositions are useful for providing protection against S. pneumoniae infection and / or pneumococcal diseases caused by S. pneumoniae including pneumococcal pneumoniae, invasive pneumococcal disease and acute otitis media.

An isolated Streptococcus pneumoniae membrane vesicle microparticle (MP), wherein said MP comprises: the protein Ply at the level of ≥0.070 μg / mg total protein in the MP; and / or the protein LytA at the level of ≥0.070 μg / mg total protein in the MP; and / or the protein PspC at the level of ≥0.130 μg / mg total protein in the MP; and / or the protein RrgB at the level of ≥0.020 μg / mg total protein in the MP. Compositions comprising such MPs. Uses thereof in particular in immunization, as well as methods of manufacture thereof.

Circadian rhythms control the diurnal nature of many physiological, metabolic and immune processes. The inventors hypothesized that age-related impairments in circadian rhythms are associated with high susceptibility to bacterial respiratory tract infections. The diurnal control of Streptococcus pneumoniae infection is impaired in elderly mice. A lung circadian transcriptome analysis revealed that aging alters the daily oscillations in the expression of a specific set of genes and that some pathways that are rhythmic in young-adult mice are nonrhythmic or time-shifted in elderly mice. In particular, the circadian expression of the clock components Rev-erb-α, and Rev-erb-β to a lesser extent, altogether with apelin / apelin receptor were altered in elderly mice compared to young mice. In young mice, the inventors discovered that novel interaction between Rev-erb and the apelinergic axis controls host defenses against S. pneumoniae via alveolar macrophages. Pharmacological repression of Rev-erb-α and / or Rev- erb-β in elderly mice resulted in greater resistance to pneumococcal infection. Thus, the present invention relates to the use of Rev-erb antagonists for the treatment of lung infections.

The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of Streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.

The invention discloses an antibacterial peptide as well as a preparation method and application thereof in preparation of a preparation for treating pneumonia, and belongs to the technical field of biological medicines. The antibacterial peptide is a mutant of endolysin derived from gram negative bacteriophage, and the endolysin of the bacteriophage plays a bacteriostatic / bactericidal role by degrading bacterial cell walls, and basically does not generate drug resistance. Common pneumonia pathogenic bacteria including moraxella catarrhalis, streptococcus pneumoniae and staphylococcus aureus are used as indicator bacteria, three antibacterial peptide mutants EAMP-M1, EAMP-M2 and EAMP-M3 with good antibacterial effects are obtained through screening, and experiments prove that the antibacterial peptide mutants have good antibacterial effects on gram-positive bacteria and gram-negative bacteria; the composition can be applied to prevention, treatment or auxiliary antibiotic treatment of common pneumonia infection; and the disinfectant is used in the field of medical instruments, such as surgical instrument disinfection, and has a wide and good market application prospect.

The present invention relates to new vaccine formulations comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Vaccine formulations of the invention typically comprise at least one glycoconjugate from an S. pneumoniae serotype in a formulation designed to facilitate resuspension. [Figure 1] TIFF2025541706000005.tif58160

This invention relates to immunogenic compositions for the prevention and treatment of infection due to Streptococcus pneumoniae containing P4 peptide and / or detoxified pneumolysin protein conjugated to a T cell stimulating epitope as a contiguous peptide sequence. In particular, non-natural amino acid sequences inserted between the structures create points of conjugation that do not interfere with the generation of an effective immune response. This invention is also directed to method for the manufacture of these compositions and administration of these compositions to subjects.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The present application relates to the field of ophthalmic drugs, and particularly relates to an ophthalmic composition, a preparation method and application thereof, the ophthalmic composition comprising a compound as shown in formula I, an osmotic pressure regulator, a pH regulator and water for injection; the pH value of the ophthalmic composition is 4.0-6.0; the concentration of the compound as shown in formula I is 0.1-3.0% w / v, and the concentration of the osmotic pressure regulator is 0.3-10.0% w / v; the antibacterial activity against Streptococcus pneumoniae, Staphylococcus aureus and Staphylococcus epidermidis is 2-8 times that of levofloxacin and moxifloxacin hydrochloride; the antibacterial activity against Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli and Pseudomonas aeruginosa is also strong, and is equivalent to that of levofloxacin and moxifloxacin hydrochloride; the irritation is small, the light stability and high-temperature stability are good, the quality and drug safety are guaranteed, and the application value is good.

The application discloses an antibacterial peptide, a preparation method thereof and application of the antibacterial peptide in preparation of a preparation for treating pneumonia, and belongs to the technical field of biological medicines. The antibacterial peptide is a mutant of endolysin derived from a gram-negative bacteriophage. The bacteriophage endolysin plays an antibacterial / killing effect by degrading bacterial cell walls, and basically does not produce drug resistance. Common pneumonia pathogenic bacteria, i.e., Moraxella catarrhalis, Streptococcus pneumoniae and Staphylococcus aureus, are used as indicator bacteria, three antibacterial peptide mutants EAMP-M1, EAMP-M2 and EAMP-M3 with better antibacterial effects are screened, experiments prove that the three antibacterial peptide mutants have better antibacterial effects on gram-positive bacteria and gram-negative bacteria, can be applied to prevention, treatment or auxiliary antibiotic treatment of common pneumonia infection, and can be used in the field of medical instruments, such as sterilization of surgical instruments, and have a wide and good market application prospect.

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

The present invention relates to novel immunogenic compositions comprising conjugated capsular saccharide antigens of Streptococcus pneumoniae (glycoconjugates) and uses thereof. The immunogenic compositions of the invention will generally comprise at least one saccharide conjugate from a serotype of Streptococcus pneumoniae that is not found in Prevnar, Synflorix and / or Prevnar 13. The invention also relates to the use of the novel immunogenic compositions for vaccinating human subjects, particularly infants and the elderly, against pneumococcal infection.